Prevention of recurrence of enteric peritonitis in peritoneal dialysis with Escherichia coli Nissle 1917: A case-series study
Abstract
INTRODUCTION
Peritonitis is still a major cause of drop-out in peritoneal dialysis (PD) and is often the consequence of the migration of bacteria across the intestinal wall, configuring an enteric peritonitis (EP). EP is usually caused by commensals of the gastrointestinal (GI) tract, it relapses commonly and may result in catheter removal.
AIMS
Currently, no specific therapeutic measures are available to effectively prevent recurrence of EP, thus we reported our clinical experience with use of probiotics Escherichia coli Nissle (EcN).
MATERIALS AND METHODS
This is a case-series study performed in PD patients affected by recurrent peritonitis due to GI commensals. In these patients, we added prophylactic treatment with EcN 100 mg twice a day (in addition to 10 days monthly of 200 mg rifaximin) to the standard management of peritonitis.
RESULTS
We enrolled 14 PD patients (mean age: 53.1 ± 11.9 years; 67% males; dialysis vintage: 7.5 (3.1 - 27.7) months; 64% automated PD). Causative organisms were Escherichia coli (N = 5), Klebsiella pneumoniae (N = 3), Enterococcus faecalis (N = 2), Enterobacter cloacae (N = 2), Aeromonas caviae (N = 1), Streptococcus gallolyticus (N = 1). No exit-site infection was associated with peritonitis. Patients were successfully treated with intra-peritoneal antibiotics adjusted to culture results and antibiotic sensitivities for 14 - 21 days. During the subsequent 18 months of follow-up, no recurrence of EP was registered. No adverse effect was…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.